Nama's AI scorecard currently rates Pennant Group Hold (5.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is PNTG's P/E ratio?

Pennant Group trades at a trailing price-to-earnings ratio of 26.5.

When does PNTG report earnings?

Pennant Group's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.37.

What is the PNTG price target?

The median analyst price target from 6 analysts is $47.00, with a range of $44.00 – $49.00.

Is PNTG Shariah compliant?

Nama's AAOIFI-style screen reads Pennant Group as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Pennant Group (PNTG)

Healthcare · Medical Care Facilities · NASDAQ

Pennant Group (PNTG) is a Healthcare company in the Medical Care Facilities industry. It has a market capitalization of $1.28B, a trailing price-to-earnings ratio of 26.5 and a free-cash-flow yield of 2.8%. Over the most recent reported fiscal year, revenue grew 36.3% and free cash flow per share grew 8.4%. Nama's AI scorecard rates it Hold, 5.2 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Hold · 5.2/10

The sections balance. As of Nov 7, 2026.

Momentum

Leading · +66.8% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-17.8%

How far the last close sits under the highest price of the past five years.

Market cap	$1.28B
Trailing P/E	26.5
Price / book	3.5
Price / sales	1.1
FCF yield	2.8%
Dividend yield	—
Gross margin	13.8%
Operating margin	5.7%
Net margin	2.9%
Revenue growth (YoY)	+36.3%
Revenue growth (3-yr annual)	+26.1%
EPS growth (YoY)	+25.5%
FCF/share growth (YoY)	+8.4%
Beta	1.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Care Facilities

PNTG earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate $0.37). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$0.35	$0.35	+0.0%	$302.25M
Q2 2026	Aug 5, 2026	$0.36	$0.33	+9.1%	$297.98M
Q1 2026	May 6, 2026	$0.32	$0.31	+3.2%	$285.36M
Q4 2025	Feb 25, 2026	$0.34	$0.32	+6.2%	$289.32M

PNTG analyst price target

Median target $47.00 from 6 analysts, ranging $44.00 – $49.00.

Medical Care Facilities peers

Ticker	Company	Market cap	P/E
HCA	HCA Healthcare	$103.40B	16.5
THC	Tenet Healthcare	$22.55B	12.7
EHC	Encompass Health	$13.50B	22.4
FMS	Fresenius Medical Care	$12.15B	10.2
DVA	DaVita	$12.04B	13.6
UHS	Universal Health Services	$11.52B	8.6
ENSG	Ensign Group	$10.56B	23.8
PACS	PACS Group	$7.87B	20.1

Explore live PNTG data on Nama Insights →

PNTG FAQ

Is PNTG a buy?: Nama's AI scorecard currently rates Pennant Group Hold (5.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is PNTG's P/E ratio?: Pennant Group trades at a trailing price-to-earnings ratio of 26.5.
When does PNTG report earnings?: Pennant Group's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.37.
What is the PNTG price target?: The median analyst price target from 6 analysts is $47.00, with a range of $44.00 – $49.00.
Is PNTG Shariah compliant?: Nama's AAOIFI-style screen reads Pennant Group as Not Shariah Compliant. At least one of the three ratios or the industry test failed.